News

เรื่องที่หลายคนไม่รู้ ปัสสาวะบ่อยหลังดื่มน้ำ แสดงว่า ไต ดีหรือไม่ดี

- by Admin - 63 Comments.

เชื่อได้ว่าหลายคนคงสงสัยกันว่า การดื่มน้ำในชีวิตประจำวัน แต่หลายคนรู้สึกวิตกกังวลเมื่อปัสสาวะหลายครั้งหลังดื่มน้ำ อยากเข้าห้องน้ำอยู่ตลอดเวลา เพราะคิดว่าอาจเป็นสัญญาณของไตอ่อนแอหรือเปล่า แล้วถ้าความถี่ในการเข้าห้องน้ำน้อยแสดงว่าไตแข็งแรงใช่หรือไม่

แน่นอนว่าพฤติกรรมการดื่มน้ำและการปัสสาวะมีความเกี่ยวเนื่องกัน ในกรณีส่วนใหญ่การกระตุ้นให้ปัสสาวะหลังดื่มน้ำเป็นปรากฏการณ์ทางสรีรวิทยาปกติ และในความเป็นจริงการปัสสาวะบ่อยๆ ไม่ได้เป็นเพียงอาการของการบาดเจ็บที่ไตเฉียบพลันเท่านั้น แต่ภาวะก้อนเนื้อในไตอาจเป็นสัญญาณของปัญหาการทำงานของไตด้วย

 

เรื่องที่หลายคนไม่รู้ ปัสสาวะบ่อยหลังดื่มน้ำ แสดงว่า ไต ดีหรือไม่ดี

โดยปกติปริมาณปัสสาวะที่ปล่อยออกมาในแต่ละวันของผู้ใหญ่ที่มีสุขภาพดี จะอยู่ระหว่าง 1,000 มล. ถึง 2,000 มล. โดยเฉลี่ยอยู่ที่ 1,500 มล. และหากคำนวณเป็นจำนวนครั้ง บุคคลหนึ่งจะปัสสาวะ 6-10 ครั้งต่อวัน และ 0-2 ครั้งในเวลากลางคืน หากความสามารถในการปัสสาวะของบุคคลนั้นตรงตามเกณฑ์เหล่านี้ แสดงว่าไตของพวกเขาทำงานได้ตามปกติ

 

เรื่องที่หลายคนไม่รู้ ปัสสาวะบ่อยหลังดื่มน้ำ แสดงว่า ไต ดีหรือไม่ดี

 

หากพบว่าตนเองมักตื่นขึ้นมาตอนกลางคืน เพราะต้องการเข้าห้องน้ำไปปัสสาวะ และอาการนี้คงอยู่เป็นเวลาหลายวันโดยไม่ดีขึ้น อีกทั้งยังส่งผลต่อกิจกรรมประจำวันของด้วย นี่อาจเป็นสัญญาณของความเสียหายของไต ความสามารถในการดูดซับปัสสาวะที่ลดลง อาจทำให้เกิดการผลิตปัสสาวะมากเกินไป ซึ่งจะเพิ่มความถี่ในการขับถ่าย

 

เรื่องที่หลายคนไม่รู้ ปัสสาวะบ่อยหลังดื่มน้ำ แสดงว่า ไต ดีหรือไม่ดี

นอกจากนี้ หากความถี่ของการปัสสาวะลดลงอย่างมีนัยสำคัญ และปริมาณปัสสาวะที่ผลิตได้น้อยกว่า 500 มล. ภายใน 24 ชั่วโมง นี่อาจเป็นสัญญาณว่าไตได้รับความเสียหายอย่างรุนแรง และอาจถึงขั้นเข้าสู่ภาวะไตวายได้ ในกรณีนี้ควรไปพบแพทย์ทันทีเพื่อตรวจและรักษา

Related Posts

แวบแรกนึกว่างู! คนไข้ถือถุงหิ้วใส่อะไรเขียวๆ มาหาหมอ พอเห็นชัดว่าคืออะไร หมอพยาบาลอึ้งทั้งแผนก

ปาฏิหาริย์เกิด สาวท้อง “นอนเป็นผัก” ครึ่งปี จู่ๆ ฟื้นคืนสติ เพราะเสียงลูกร้องตอนคลอด

“แผ่นดินไหว” 8 ต.ค. 68 ไทยใกล้ศูนย์กลาง ทั่วโลกรหัสแดง สะเทือนมาก 6.6

About Admin

View all posts by Admin →

63 Comments on “เรื่องที่หลายคนไม่รู้ ปัสสาวะบ่อยหลังดื่มน้ำ แสดงว่า ไต ดีหรือไม่ดี”

  14. Poster Keerthana Deepti Karunakaran BioMedical Engineering And Imaging Institute

    **Keerthana Deepti Karunakaran**

    Dr. Keerthana Deepti Karunakaran is a leading translational oncologist
    and researcher whose work bridges the gap between bench‑science
    discoveries and bedside applications in cancer care. She earned her Ph.D.
    in Molecular Oncology from the University of Pennsylvania, followed by postdoctoral training in Immunology at Stanford University where she investigated the role
    of tumor microenvironmental cues in shaping anti‑tumor immunity.

    Her laboratory focuses on three interconnected pillars:

    | **Research Pillar** | **Key Focus Areas** | **Clinical Translation** |
    |———————|———————-|————————–|
    | 1. Tumor–Immune Interactions | Neoantigen landscape mapping; immune checkpoint ligand
    profiling | Development of patient‑specific neoantigen vaccines; biomarkers for ICI response |
    | 2. Metabolic Reprogramming | Cancer cell glycolysis, lipid metabolism, and their impact on immune
    suppression | Identification of metabolic inhibitors that synergize with immunotherapy |
    | 3. Nanoparticle Delivery Platforms | Targeted drug encapsulation; controlled release
    systems; imaging-guided delivery | Clinical trials
    for combination chemo‑immunotherapy via nanoparticle carriers |

    **Key Innovations:**

    – **Single‑cell multi‑omics integration:** Combines scRNA‑seq, TCR/BCR
    profiling, and spatial transcriptomics to map tumor–immune interactions.

    – **Metabolic flux analysis:** Uses stable isotope labeling (e.g., ^13C‑glucose) coupled with
    mass spectrometry to quantify metabolic pathways active
    in tumor vs. infiltrating immune cells.
    – **Programmable nanoparticles:** Designed using DNA
    origami or lipid‑polymer hybrid systems that
    release payloads upon sensing specific tumor microenvironment cues (pH, enzymes).

    —

    ### 4. Experimental Plan for the Novel Cancer Therapy

    #### Objective
    Develop a combinatorial therapy that simultaneously:
    1. Inhibits oncogenic signaling in tumor cells.
    2. Reinvigorates exhausted T cells via immune checkpoint blockade.

    3. Modulates the metabolic environment to favor anti‑tumor immunity.

    #### Overview of Approach
    – **Targeted delivery**: Use ligand‑decorated, biodegradable nanoparticles
    loaded with a small‑molecule inhibitor (e.g., MEK/ERG inhibitor) and an siRNA/shRNA targeting an immune checkpoint molecule (PD‑L1 or
    CTLA‑4).
    – **Metabolic reprogramming**: Incorporate a metabolic modulator (e.g.,
    metformin or 2‑deoxyglucose) to reduce tumor glycolysis, lowering lactate levels.

    – **Immunostimulatory component**: Include an adjuvant such as CpG oligonucleotide to activate dendritic
    cells and enhance T cell responses.

    ### Experimental Plan

    | **Aim** | **Experimental Design** | **Controls** |
    |—|—|—|
    | 1. Validate the synergistic effect of combined ERK inhibition and immune modulation in vitro.
    | • Treat engineered melanoma (BRAF‑mutated) or NSCLC
    cells with:
     a) ERK inhibitor alone;
     b) Immune adjuvant alone;
     c) Combination.
    • Measure cell viability, apoptosis, cytokine secretion.
    • Co-culture tumor cells with autologous T cells to assess cytotoxicity (LDH release,
    IFN‑γ ELISpot). | Untreated control; each agent alone.

    |
    | 2. Assess the effect on immune checkpoint
    pathways and antigen presentation. | • Flow cytometry for PD‑L1, MHC‑I/II after treatments.

    • qPCR for interferon‑stimulated genes. | Baseline expression. |
    | 3. Evaluate in vivo efficacy using syngeneic mouse models
    (e.g., MC38 or B16‑F10). | • Treat with combination therapy (chemotherapy + checkpoint inhibitor).

    • Monitor tumor growth, survival, T‑cell infiltration (IHC for
    CD8+, FoxP3).
    • Perform ELISPOT for tumor‑specific T cells. | Control groups: vehicle, single agents.
    |

    **Outcome Measures**

    – **Tumor Growth Delay / Complete Remission Rates**
    – **Overall Survival**
    – **Immune Profiling (CD8⁺/Treg ratio, cytokine levels)**
    – **Pathological Assessment of Tumors and Adjacent
    Tissue**

    —

    ### 3. Expected Findings

    | Aspect | Predicted Outcome |
    |——–|——————-|
    | **Tumor Volume** | Combination therapy should
    produce the greatest reduction in tumor size, with
    a higher proportion of complete regressions compared to single
    agents. |
    | **Survival** | Mice receiving combination treatment will display significantly longer
    overall survival (median OS increase >30 %).

    |
    | **Immune Response** | Enhanced infiltration of CD8⁺ T cells, increased
    IFN‑γ production, advanced test and dianabol cycle a lower Treg/CD8 ratio in tumors; peripheral blood should show elevated
    effector memory T cells. |
    | **Molecular Changes** | Up‑regulation of antigen presentation genes (e.g., MHC class I), higher expression of PD‑L1 on tumor cells (indicative of
    an active immune microenvironment). |
    | **Safety/Toxicity** | No significant weight loss or organ toxicity; serum chemistry within normal limits, indicating tolerable combination therapy.

    |

    These outcomes would suggest that the combination therapy not
    only directly targets tumor growth but also primes and sustains an adaptive anti‑tumor immune response, thereby providing a rationale for further clinical development.

    —

    ### 3. Potential Challenges & Contingency Plans

    | **Challenge** | **Potential Impact** | **Mitigation / Alternative Strategy** |
    |—————|———————-|—————————————|
    | **Insufficient Tumor Infiltration of Immune Cells** |
    May limit observed therapeutic benefit. | *Pre‑treat with
    low‑dose irradiation or adoptive transfer of activated T cells
    to enhance infiltration.* |
    | **Toxicity from Combined Agents** | Could limit dosing or require discontinuation. | *Implement dose‑escalation studies; use alternative,
    less toxic analogues (e.g., a different 5‑FU derivative).* |
    | **Emergence of Resistance Mechanisms** | Diminished efficacy over time.
    | *Incorporate combination with checkpoint inhibitors to counteract immunosuppression.* |
    | **Variability in Tumor Microenvironment** | Could confound results across
    mice. | *Use genetically engineered mouse models (GEMMs) with
    defined stromal components; stratify analysis accordingly.* |

    —

    ### 4. **Conclusion**

    By integrating **metabolic, pharmacologic, and immunologic insights**, this experimental framework seeks to determine whether the **combination of metabolic
    inhibitors and cytotoxic agents** can synergistically remodel the tumor
    microenvironment, enhancing both drug delivery and anti‑tumor immune responses.
    The results will illuminate the mechanistic basis for combined therapeutic
    strategies that exploit tumor metabolism and could inform future translational studies targeting metabolic vulnerabilities in solid tumors.

  42. After just two weeks of using Anavar, many users—especially women—begin to notice subtle yet encouraging changes that
    set the tone for the rest of their cycle. The early effects are often a mix of improved body composition, increased energy levels, and mild aesthetic enhancements that make the commitment feel worthwhile.

    Anavar Results After 2 Weeks For Females

    During the first fortnight, most female users report an immediate boost in stamina during workouts, allowing them to push
    through sets with greater confidence. Because Anavar is known for its gentle nature compared to
    other anabolic steroids, women typically experience
    a reduction in body fat that manifests as a more toned midsection and slimmer waistline.
    Muscle definition starts to become visible, particularly around the arms, shoulders, and
    calves. Even though significant muscle growth usually
    takes longer, the early weeks provide a noticeable tightening of soft tissues, giving users a clearer sense of progress.

    Anavar for Women

    Women often choose Anavar for its low androgenic activity,
    which minimizes the risk of virilization—a common concern with more potent steroids.
    The compound’s mild nature means that side effects such as acne or hair loss
    are usually mild and manageable when proper skin care is followed.

    For those looking to enhance athletic performance without drastic weight gain,
    Anavar offers a balanced approach: it supports lean muscle retention while promoting fat loss.

    Many female athletes report feeling lighter and more agile after just two
    weeks, which translates into better sprint times, improved endurance, and quicker recovery between sessions.

    Average Dosage

    The recommended starting dose for women is typically lower than for
    men due to differences in body composition and hormone sensitivity.
    A common regimen begins at 10 mg per day for the
    first week and may increase to 20–25 mg per day by the second week, depending on individual tolerance.
    Some users find that staying within this range provides sufficient stimulus for fat loss while keeping side effects minimal.

    It is essential to monitor how your body reacts; if any signs of excess virilization or liver strain appear,
    reducing the dose or stopping the cycle is advised.

    In summary, after two weeks on Anavar, female users can expect enhanced workout performance,
    visible muscle definition, and a reduction in body
    fat—all achieved with a dosage that prioritizes safety.
    These early results are often enough to motivate continued use while maintaining
    awareness of personal limits and health considerations.

    References:

    male

  49. The long‑term safety profile of the growth hormone secretagogue pair,
    commonly referred to as CJC‑1295 and Ipamorelin, has been a subject of
    ongoing discussion within both clinical research circles and
    the broader community of users who incorporate these
    peptides into their regimens. Although short‑term studies have
    generally reported favorable outcomes with minimal adverse events, extended use raises questions about potential cumulative effects on various physiological systems.

    Long term side effects CJC‑1295/Ipamorelin

    Hormonal imbalances

    Repeated stimulation of the pituitary gland can lead to a degree of desensitization or dysregulation over time.
    Users may experience alterations in natural growth
    hormone secretion patterns, potentially resulting in elevated basal
    levels or diminished responsiveness when exogenous peptides
    are withdrawn. In some reports, prolonged administration has been linked
    with mild hypothalamic‑pituitary axis fatigue, which could
    manifest as changes in sleep architecture, mood
    fluctuations, or altered libido.

    Metabolic disturbances

    Growth hormone plays a central role in lipid and glucose metabolism.
    Chronic exposure to exogenous GH secretagogues may influence insulin sensitivity, occasionally
    leading to transient hyperglycemia or increased lipolysis that can alter body composition. While many users note lean mass
    gains, there have been isolated cases of fatty liver changes or mild elevations in triglyceride levels after extended use.

    Edema and fluid retention

    A well‑documented short‑term effect of GH stimulation is peripheral edema due
    to vasodilation and increased capillary permeability.
    When CJC‑1295/Ipamorelin are used over months, some individuals report persistent
    or recurrent swelling in the extremities, which can be uncomfortable and may indicate a shift toward chronic fluid retention.

    Carcinogenic concerns

    The theoretical risk that sustained growth hormone elevation could promote tumorigenesis has been raised by a
    few animal studies. While human data remain limited, long‑term surveillance of users who have maintained therapy for more
    than a year suggests no definitive increase in cancer incidence; nevertheless,
    the possibility remains an area requiring cautious monitoring.

    Cardiovascular implications

    Growth hormone influences vascular tone and can affect arterial stiffness.

    Over extended periods, some users have reported changes in blood
    pressure readings, occasionally indicating mild hypertension or diastolic dysfunction. Regular cardiovascular assessment is
    advisable for those on long‑term therapy.

    Musculoskeletal effects

    While growth hormone supports muscle repair, chronic overstimulation might theoretically lead to aberrant connective tissue remodeling.
    Rare reports of joint stiffness or arthralgia have surfaced in anecdotal forums, though no large‑scale studies confirm a direct causal link.

    Immune system modulation

    GH secretagogues can alter cytokine profiles, potentially affecting immune
    surveillance. There is limited evidence suggesting that long‑term use might modestly shift inflammatory markers,
    which could influence susceptibility to infections or autoimmune phenomena in susceptible individuals.

    Psychological and neurocognitive impact

    Growth hormone has neuroprotective roles, but chronic exogenous elevation may lead to mood swings, irritability, or mild anxiety in some users.
    These effects are usually reversible upon discontinuation of therapy.

    Top Posts

    “Long‑Term Use of CJC‑1295/Ipamorelin: A Review of Clinical Evidence” – This
    post compiles peer‑reviewed studies and meta‑analyses focusing on the
    safety profile after 12 months of continuous administration, highlighting
    hormonal feedback loops and metabolic markers.

    “User Experiences with Extended GH Secretagogue Therapy” – An aggregated discussion board thread where individuals share personal anecdotes
    regarding edema, mood changes, and body composition shifts over multi‑year usage, providing real‑world context to the clinical data.

    “Monitoring Protocols for Chronic CJC‑1295/Ipamorelin Treatment” – A comprehensive guide outlining recommended blood panels
    (IGF‑1, insulin sensitivity indices, lipid profile), imaging schedules (ultrasound of liver and heart), and periodic endocrine evaluations tailored for
    long‑term peptide therapy.

    “Potential Carcinogenic Risks Associated with Growth Hormone Secretagogues”
    – An evidence‑based article dissecting the limited animal data, human observational studies, and current regulatory stance on GH
    secretagogue safety over extended periods.

    “Balancing Muscle Gain and Joint Health: A Longitudinal Study of CJC‑1295/Ipamorelin Users”
    – Presents longitudinal observations linking sustained peptide use with reported joint discomfort, exploring possible preventative strategies such
    as targeted physiotherapy or dosage modulation.

    These resources collectively provide a nuanced view of the potential long‑term side effects associated with CJC‑1295 and Ipamorelin. They emphasize the importance of individualized monitoring, awareness of hormonal feedback mechanisms, and ongoing research
    to fully elucidate the safety profile over extended periods.

    References:

    valley

Leave a Reply

Your email address will not be published. Required fields are marked *